This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background: Aggregation and fibrillization of the α-synuclein protein (encoded by the SNCA gene) may represent key events in the pathogenesis of Parkinson disease (PD). Variability in the length of a dinucleotide repeat sequence (REP1) within the SNCA promoter confers susceptibility to sporadic PD. Pesticide exposures may also confer susceptibility to PD. Our objective was to test possible joint effects of SNCA REP1 genotypes and pesticide exposures on the risk of PD.
Methods: This was a case–control study. Cases were recruited prospectively from the Department of Neurology of the Mayo Clinic, Rochester, MN, after June 1, 1996. The control subjects included unaffected siblings of cases and unrelated population control subjects. We assessed pesticide exposures by telephone interview and genotyped SNCA REP1. Odds ratios (ORs) and 95% CIs were determined using conditional logistic regression models.
Results: There were 833 case–control pairs. We observed an increased risk of PD with increasing SNCA REP1 bp length (OR, 1.18 for each score unit; 95% CI, 1.02–1.37; p = 0.03). Pesticide exposures were associated with PD in younger subjects only (lowest quartile of age at study, ≤59.8 years; OR, 1.80; 95% CI, 1.12–2.87; p = 0.01 for all pesticides; OR, 2.46; 95% CI, 1.34–4.52; p = 0.004 for herbicides). In multivariate analyses, both SNCA REP1 score and pesticide exposures were significantly associated with PD in younger subjects, but there were no pairwise interactions.
Conclusions: Our findings suggest that SNCA REP1 genotype and herbicides have independent effects on risk of Parkinson disease, primarily in younger subjects.
Footnotes
-
dmaraganore{at}mayo.edu
e-Pub ahead of print on March 5, 2008, at www.neurology.org.
Supported by grants NS 33978 and ES 10751 (National Institutes of Health).
Disclosure: Dr. Maraganore is the co-inventor of a US provisional patent application entitled “Method of treating neurodegenerative disease.” It has been licensed to Alnylam Pharmaceuticals, Inc. and he has received less than $10,000 in royalty payments. Dr. Maraganore has consulted for Alnylam Pharmaceutical, Inc., Pfizer, Inc., and Merck and Co., Inc. during the last 5 years but received no personal compensation. Dr. Farrer is the co-inventor of a US provisional patent application entitled “Method of treating neurodegenerative disease.” It has been licensed to Alnylam Pharmaceuticals, Inc. and he has received royalty payments in excess of $10,000. Dr. Farrer has a consulting relationship with Amgen, Inc. for which no payments have been made to date. Mayo Clinic has received royalty payments in excess of $10,000 from Alnylam Pharmaceuticals, Inc., in relation to the US provisional patent application entitled “Method of treating neurodegenerative disease.”
Received June 23, 2007. Accepted in final form November 1, 2007.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age
The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living
Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease
Persistent organochlorine pesticides in serum and risk of Parkinson disease